Beksagliflozin etkileşimleri

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (Flukonazol etiketi, İlaç etkileşimleri)

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. (Glipizid ve metformin etiketi, Kontrendikasyonlar)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (Hidroksiklorokin etiketi, Uyarılar ve önlemler)

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (Klorokin etiketi, Uyarılar)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (Siprofloksasin etiketi, İlaç etkileşimleri)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (Abirateron etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (Amlodipin ve benazepril etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (Asitretin etiketi, İlaç etkileşimleri)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (Aspirin ve dipiridamol etiketi, İlaç etkileşimleri)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Atazanavir etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (Benazepril etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Brimonidin ve timolol etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (Butalbital, aspirin ve kafein etiketi, İlaç etkileşimleri)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

Caution should be exercised when used with antidiabetic drugs. (Danazol etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (Darunavir etiketi, Uyarılar ve önlemler)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Darunavir ve kobisistat etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Dorzolamid ve timolol etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (Fludrokortizon etiketi, İlaç etkileşimleri)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (Fluoksetin etiketi, Uyarılar ve önlemler)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (Fosamprenavir etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (Hidrokortizon etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (İtrakonazol etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (Kapesitabin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (Ketokonazol etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (Klaritromisin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotid etiketi, Uyarılar ve önlemler)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (Levofloksasin etiketi, Uyarılar ve önlemler)

Worsening of Diabetic Control : May worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (Levotiroksin etiketi, Uyarılar ve önlemler)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Levotiroksin ve liyotironin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (Linezolid etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (Lisinopril etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Lithium Clinical Impact Concomitant use with SGLT2 inhibitors such as bexagliflozin tablets may decrease serum lithium concentrations. (Beksagliflozin etiketi, İlaç etkileşimleri)

• Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (Liyotironin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Metilprednizolon etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Antidiabetic agents Carefully monitor blood glucose. (Moksifloksasin etiketi, İlaç etkileşimleri)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (Nadolol etiketi, Uyarılar)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (Naltrekson ve bupropion etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (Ofloksasin etiketi, Uyarılar)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Oktreotid etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (Orlistat etiketi, Uyarılar ve önlemler)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (Pindolol etiketi, Uyarılar)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Prednizolon etiketi, İlaç etkileşimleri)

Antidiabetic agents: May increase blood glucose concentrations. (Prednizon etiketi, İlaç etkileşimleri)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (Pregabalin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (Salsalat etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (Beksagliflozin etiketi, İlaç etkileşimleri)

The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin etiketi, Uyarılar ve önlemler)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (Sotalol etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (Sülfametoksazol ve trimetoprim etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus etiketi, Uyarılar ve önlemler)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (Timolol etiketi, Uyarılar ve önlemler)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (Beksagliflozin etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (Trandolapril etiketi, İlaç etkileşimleri)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (Tranilsipromin etiketi, Uyarılar ve önlemler)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (Triamsinolon etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (Vorikonazol etiketi, İlaç etkileşimleri)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (Bupropion etiketi, Uyarılar ve önlemler)

Antidiabetic drug requirements (i.e., insulin) may be altered. (Dietilpropion etiketi, İlaç etkileşimleri)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (Fendimetrazin etiketi, İlaç etkileşimleri)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (Klozapin etiketi, Uyarılar ve önlemler)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (Lovastatin etiketi, İlaç etkileşimleri)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (Mikonazol etiketi, İlaç etkileşimleri)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (Moeksipril etiketi, İlaç etkileşimleri)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (Nifedipin etiketi, Önlemler)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (Sülfadiazin etiketi, İlaç etkileşimleri)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (Telmisartan ve amlodipin etiketi, İlaç etkileşimleri)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (Tolmetin etiketi, İlaç etkileşimleri)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (Ziprasidon etiketi, Uyarılar ve önlemler)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (Sulindak etiketi, İlaç etkileşimleri)